KR101712231B1 - 카바지탁셀의 신규한 항종양 용도 - Google Patents

카바지탁셀의 신규한 항종양 용도 Download PDF

Info

Publication number
KR101712231B1
KR101712231B1 KR1020127013564A KR20127013564A KR101712231B1 KR 101712231 B1 KR101712231 B1 KR 101712231B1 KR 1020127013564 A KR1020127013564 A KR 1020127013564A KR 20127013564 A KR20127013564 A KR 20127013564A KR 101712231 B1 KR101712231 B1 KR 101712231B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
solvate
administered
composition according
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127013564A
Other languages
English (en)
Korean (ko)
Other versions
KR20120093986A (ko
Inventor
선일 구프타
Original Assignee
아벤티스 파마 소시에떼아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43567614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101712231(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아벤티스 파마 소시에떼아노님 filed Critical 아벤티스 파마 소시에떼아노님
Publication of KR20120093986A publication Critical patent/KR20120093986A/ko
Application granted granted Critical
Publication of KR101712231B1 publication Critical patent/KR101712231B1/ko
Assigned to 사노피 메이쳐 아이피 reassignment 사노피 메이쳐 아이피 권리의 전부이전등록 Assignors: 아방티 파마 에스아에흐엘
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
KR1020127013564A 2009-10-29 2010-10-27 카바지탁셀의 신규한 항종양 용도 Active KR101712231B1 (ko)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US25616009P 2009-10-29 2009-10-29
US61/256,160 2009-10-29
US29390310P 2010-01-11 2010-01-11
US61/293,903 2010-01-11
US35588810P 2010-06-17 2010-06-17
US35583410P 2010-06-17 2010-06-17
US61/355,834 2010-06-17
US61/355,888 2010-06-17
US36992910P 2010-08-02 2010-08-02
US61/369,929 2010-08-02
US38393310P 2010-09-17 2010-09-17
US61/383,933 2010-09-17
US38996910P 2010-10-05 2010-10-05
US61/389,969 2010-10-05
PCT/IB2010/054866 WO2011051894A1 (en) 2009-10-29 2010-10-27 Novel antitumoral use of cabazitaxel

Publications (2)

Publication Number Publication Date
KR20120093986A KR20120093986A (ko) 2012-08-23
KR101712231B1 true KR101712231B1 (ko) 2017-03-03

Family

ID=43567614

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127013564A Active KR101712231B1 (ko) 2009-10-29 2010-10-27 카바지탁셀의 신규한 항종양 용도

Country Status (31)

Country Link
US (8) US8927592B2 (https=)
EP (1) EP2493466B1 (https=)
JP (2) JP5566466B2 (https=)
KR (1) KR101712231B1 (https=)
CN (1) CN102770131A (https=)
AR (1) AR078824A1 (https=)
AU (4) AU2010310986A1 (https=)
BR (1) BR112012011457A2 (https=)
CA (1) CA2779009A1 (https=)
CR (1) CR20120204A (https=)
DK (1) DK2493466T3 (https=)
EA (1) EA024186B1 (https=)
EC (1) ECSP12011836A (https=)
ES (1) ES2862340T3 (https=)
GT (1) GT201200123A (https=)
IL (3) IL219443A0 (https=)
MA (1) MA33767B1 (https=)
MX (1) MX336339B (https=)
MY (1) MY164086A (https=)
NI (1) NI201200071A (https=)
PE (1) PE20121429A1 (https=)
PH (1) PH12012500848A1 (https=)
PL (1) PL2493466T3 (https=)
PT (1) PT2493466T (https=)
SG (1) SG10201810928SA (https=)
SV (1) SV2012004192A (https=)
TN (1) TN2012000188A1 (https=)
TW (2) TWI533866B (https=)
UY (1) UY32987A (https=)
WO (1) WO2011051894A1 (https=)
ZA (1) ZA201203123B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2926551A1 (fr) 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
US20120065255A1 (en) * 2009-10-19 2012-03-15 Nagesh Palepu Cabazitaxel formulations and methods of preparing thereof
CN102770131A (zh) 2009-10-29 2012-11-07 安万特医药股份有限公司 卡巴他赛的新颖抗肿瘤用途
JP2014514306A (ja) * 2011-04-12 2014-06-19 プラス・ケミカルス・エスアー 固体形態のカバジタキセル及びその製造方法
CN102503913B (zh) * 2011-10-20 2014-03-26 江苏红豆杉生物科技股份有限公司 直接用于x射线单晶衍射分析的二甲氧基紫杉烷类化合物单晶晶体的制备方法
JP6025861B2 (ja) * 2011-12-13 2016-11-16 アベンティス・ファーマ・ソシエテ・アノニム カバジタキセルの結晶形およびこれを調製するための方法
WO2013111157A1 (en) * 2012-01-03 2013-08-01 Shilpa Medicare Limited Process for preparing amorphous cabazitaxel
CN104583189A (zh) 2012-07-31 2015-04-29 永信药品工业股份有限公司 非晶型的卡巴利他索
TW201438714A (zh) * 2013-03-04 2014-10-16 Aventis Pharma Sa 卡巴他賽（ｃａｂａｚｉｔａｘｅｌ）及其治療轉移性前列腺癌之用途
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
PT3258931T (pt) * 2015-02-17 2020-09-23 Univ Erasmus Med Ct Rotterdam Utilização do cabazitaxel no tratamento do cancro da próstata
EP3093014A1 (en) 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
EP3509569A1 (en) 2016-09-07 2019-07-17 Cadila Healthcare Limited Sterile injectable compositions comprising drug micelles
US10195214B2 (en) 2017-03-01 2019-02-05 Corcept Therapeutics, Inc. Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
US20210088505A1 (en) * 2017-04-07 2021-03-25 La Jolla Institute For Allergy And Immunology Unipotent Neutrophil Progenitor Cells, Methods of Preparation, and Uses Thereof
US20250017891A1 (en) * 2023-07-04 2025-01-16 Twi Pharmaceuticals, Inc. Pharmaceutical composition comprising cabazitaxel prodrug-cyclodextrin inclusion complex, and applications thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5005588A (en) 1989-10-13 1991-04-09 David Rubin Method for increasing tumor sensitivity to chemotherapy
US5714512A (en) 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5750561A (en) 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
ZA94128B (en) 1993-02-01 1994-08-19 Univ New York State Res Found Process for the preparation of taxane derivatives and betalactam intermediates therefor
FR2732340B1 (fr) 1995-03-27 1997-04-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
MA23823A1 (fr) 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
US5847170A (en) 1995-03-27 1998-12-08 Rhone-Poulenc Rorer, S.A. Taxoids, their preparation and pharmaceutical compositions containing them
US6372780B2 (en) 1995-03-27 2002-04-16 Aventis Pharma S.A. Methods of treating cell lines expressing multidrug resistance P-glycoprotein
FR2745814B1 (fr) 1996-03-06 1998-04-03 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2771092B1 (fr) 1997-11-18 1999-12-17 Rhone Poulenc Rorer Sa Procede de preparation de derives de la classe des taxoides
US6346543B1 (en) 1998-08-17 2002-02-12 Aventis Pharma S.A. Use of a taxoid to treat abnormal cell proliferation in the brain
WO2000010547A2 (en) 1998-08-20 2000-03-02 Aventis Pharma S.A. New use of taxoid derivatives
US6403634B1 (en) 1999-01-13 2002-06-11 Aventis Pharma S.A. Use of taxoid derivatives
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
SI1493556T1 (sl) 2003-07-02 2006-02-28 Scheuten Glasgroep Bv Postopek za pripravo protipozarne zasteklitve
EP1498120A1 (en) 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid formulations for the oral administration of taxoids
FR2859996B1 (fr) * 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
SG156625A1 (en) 2004-12-08 2009-11-26 Aventis Pharma Inc Method for measuring resistance or sensitivity to docetaxel
EP1700596A1 (en) 2005-03-09 2006-09-13 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Use of microtubule stabilizing compounds for the treatment of lesions of CNS axons
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
FR2922107B1 (fr) 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides
FR2926551A1 (fr) 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
EP2177630A1 (en) * 2008-10-02 2010-04-21 Institut Gustave Roussy Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
CN103932972A (zh) 2009-03-30 2014-07-23 天蓝制药公司 聚合物-药剂缀合物、颗粒、组合物和相关使用方法
FR2945211A1 (fr) 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
US20110160159A1 (en) 2009-09-15 2011-06-30 John Ryan Treatment of cancer
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
CN102770131A (zh) 2009-10-29 2012-11-07 安万特医药股份有限公司 卡巴他赛的新颖抗肿瘤用途
ES2621613T3 (es) 2009-11-04 2017-07-04 Emcure Pharmaceuticals Limited Un proceso mejorado para la preparación de derivados de taxano
AU2010321533A1 (en) 2009-11-23 2012-05-31 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
WO2011124669A1 (en) 2010-04-08 2011-10-13 Institut Gustave Roussy Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
WO2011130317A2 (en) 2010-04-13 2011-10-20 Amplyx Pharmaceuticals Inc. Therapeutic agents having reduced toxicity
AU2011239569B2 (en) 2010-04-16 2014-07-24 Baylor College Of Medicine Method for treating solid tumors
EP3093014A1 (en) 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
EP3808345A1 (en) 2019-10-15 2021-04-21 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Clin Cancer Res. vo.15, no.2, pp.723-730 (2009.01.15.).
Jpn J Clin Oncol. vo.37, no.8, pp.603-608 (2007.).

Also Published As

Publication number Publication date
US20190151278A1 (en) 2019-05-23
US20200155497A1 (en) 2020-05-21
MX2012005030A (es) 2012-12-05
PT2493466T (pt) 2021-03-29
SV2012004192A (es) 2012-08-23
US8927592B2 (en) 2015-01-06
TWI533866B (zh) 2016-05-21
AR078824A1 (es) 2011-12-07
MY164086A (en) 2017-11-30
JP2014196323A (ja) 2014-10-16
JP6182510B2 (ja) 2017-08-16
KR20120093986A (ko) 2012-08-23
NI201200071A (es) 2012-08-20
DK2493466T3 (da) 2021-04-26
CA2779009A1 (en) 2011-05-05
TWI654975B (zh) 2019-04-01
EP2493466B1 (en) 2021-03-10
SG10201810928SA (en) 2019-01-30
US12453712B2 (en) 2025-10-28
AU2019203514A1 (en) 2019-06-06
US20210169843A1 (en) 2021-06-10
JP5566466B2 (ja) 2014-08-06
US20150118182A1 (en) 2015-04-30
PE20121429A1 (es) 2012-11-06
EP2493466A1 (en) 2012-09-05
US10583110B2 (en) 2020-03-10
AU2010310986A1 (en) 2012-06-14
PH12012500848A1 (en) 2016-02-08
IL267583A (en) 2019-08-29
TW201611831A (en) 2016-04-01
TN2012000188A1 (en) 2013-12-12
CN102770131A (zh) 2012-11-07
ES2862340T3 (es) 2021-10-07
EA024186B1 (ru) 2016-08-31
AU2016200598A1 (en) 2016-02-25
ZA201203123B (en) 2013-06-26
PL2493466T3 (pl) 2021-11-15
MX336339B (es) 2016-01-14
BR112012011457A2 (pt) 2016-05-03
UY32987A (es) 2011-05-31
CR20120204A (es) 2012-07-04
IL219443A0 (en) 2012-06-28
IL250254A0 (en) 2017-03-30
US20150104411A1 (en) 2015-04-16
EA201270606A1 (ru) 2013-01-30
ECSP12011836A (es) 2012-07-31
AU2017232227B2 (en) 2019-06-06
US20120301425A1 (en) 2012-11-29
TW201127374A (en) 2011-08-16
US10716777B2 (en) 2020-07-21
AU2017232227A1 (en) 2017-10-12
WO2011051894A1 (en) 2011-05-05
US20180125810A1 (en) 2018-05-10
JP2013509394A (ja) 2013-03-14
US20240139146A1 (en) 2024-05-02
MA33767B1 (fr) 2012-11-01
GT201200123A (es) 2013-11-07

Similar Documents

Publication Publication Date Title
KR101712231B1 (ko) 카바지탁셀의 신규한 항종양 용도
EP3076972B1 (en) Cancer treatment with combination of plinabulin and taxane
CN105792845A (zh) 使用低氧活化的前药与紫杉烷类化合物的组合治疗胰腺癌
EP3808345A1 (en) Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent
AU2015200149B2 (en) Novel antitumoral use of cabazitaxel
KR20180006417A (ko) 카바지탁셀 및 암 치료에 대한 그의 용도
HK1173071B (en) Novel antitumoral use of cabazitaxel
HK1173071A (en) Novel antitumoral use of cabazitaxel
CA2708489A1 (en) Use of cabazitaxel and a prednisone or a prednisolone in the treatment of prostate cancer
EP3797834A1 (en) Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent
UA110606C2 (uk) Нове протипухлинне застосування кабазитакселу
HK1229712B (en) Cancer treatment with combination of plinabulin and taxane

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20200129

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 10